Editas Medicine (EDIT) Tops Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Editas Medicine (EDIT) PT Lowered to $15 at Stifel
May 4, 2022 3:53 PM EDTStifel analyst Dae Gon Ha lowered the price target on Editas Medicine (NASDAQ: EDIT) to $15.00 (from $19.00) while maintaining a Hold rating.
The analyst commented, "No changes to our thesis pending clarity on the therapeutic profile of EDIT-101 (Leber congenital amaurosis type 10 [LCA10])... More
